Intensity Therapeutics FY 2023 net loss $10.5M; cash $14.8M funds ops through Q1 2025

INTENSITY THERAPEUTICS, INC.

Net loss $10.5M in 2023 vs $7.6M in 2022; includes $2.3M non-cash loss on debt conversion.
Year-end cash & investments $14.8M; company expects runway to end of Q1 2025.
R&D expenses $4.8M (vs $5.1M); G&A $3.5M (vs $2.4M) due to public-company costs.
Phase 3 sarcoma trial (INVINCIBLE-3) targeting 333 patients, overall survival endpoint; enrollment starts mid-2024.
Phase 2/3 breast cancer program (INVINCIBLE-4) to begin mid-2024; endpoint pathological complete response rate.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

INTENSITY THERAPEUTICS, INC. reported financial results for year ended December 31, 2023.

Period: year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 14, 2024, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the year ended December 31, 2023.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

INTENSITY THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-24-011219

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.